New hope for Tough-to-Treat lung cancer: drug combo trial shows promise
NCT ID NCT06448910
Summary
This study is testing whether adding a new immunotherapy drug called cadonilimab (AK104) to standard chemotherapy and radiation can better control advanced, inoperable lung cancer. It involves 41 patients who will receive the drug before, during, and for a year after their standard treatment. The main goals are to see if the combination shrinks tumors effectively and is safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, China
Conditions
Explore the condition pages connected to this study.